Agree with this. I think the biggest risk to investors is that IMU turns out to be just one of hundreds of companies in the cancer space with something to offer, but doesn’t have the “holy grail” so to speak - remember, there is a lot of terrific work/research being done in this space all across the world.
BP may get interested on release of some great data, but maybe further data is just ok and we blend into the crowd to some extent. That may still produce a commercial outcome, but perhaps not as life changing as many had hoped. I still have my fingers crossed.
IMU Price at posting:
3.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)